The new facility for Shanghai Promega Biological Products will replace present molecular biology reagent production site and also provide additional research, development and cGMP manufacturing capabilities for molecular diagnostics products for the Chinese market.
The building, which is equipped for the manufacture of molecular biology and molecular diagnostic reagents, is expected to begin production in the next few weeks.
Promega CEO Bill Linton said China is an integral part of Promega’s manufacturing and business operations.
"This recent investment in the new Shanghai cGMP manufacturing facility represents Promega’s continued commitment to life science in China," Linton added.
The new facility is one of five Promega manufacturing sites across the globe.